Profile: Citra Anticoagulants, Inc. develops and markets citrate-based anticoagulants for the medical sector. Our products are used in the preparation of platelet rich plasma as an aid in wound healing, and in the collection of granulocytes. Our triCitrasol® anticoagulant sodium citrate concentrate, 46.7% trisodium citrate (30.5% free citrate ion), is a sterile, non-pyrogenic solution, used in granulocytapheresis procedures. It is latex free. Our noClot-50™ anticoagulant citrate dextrose solution is used as an anticoagulant in the extracorporeal blood processing with autologous PRP systems in the preparation of platelet rich plasma (PRP).

The company was founded in 1997, has revenues of USD 1-5 Million and is ISO 9002 certified.

FDA Registration Number: 3011400126